Clinical Manifestations, Laboratory Findings and Disease Course of Iranian Pediatric Patients Diagnosed with Hepatitis A Infection
AbstractBackground: According to some provincial reports, prevalence of hepatitis A has had a decreasing trend during the past decade in Iran. We aimed to overview clinical manifestations and laboratory findings of Iranian pediatric patients diagnosed with hepatitis A infection. Materials and Methods: This retrospective study was performed on 162 consecutive pediatric cases of hepatitis A infection. Data were collected by reviewing hospital records on admission to hospital. Results: The mean±SD age of participants was 9.90±4.08 years and 55.6% were boys. Regarding clinical manifestations, the most frequent symptom was jaundice. Fever was more prevalent in girls than in boys; whereas, abdominal tenderness was more prevalent in boys compared to girls. There was no difference in the prevalence of other clinical indices as well as in laboratory parameters between two sexes. Diarrhea was significantly more frequent in children younger than 2 years compared with other age subgroups. However, abdominal tenderness was more frequent in older patients compared to younger children. Regarding laboratory parameters, except for serum direct bilirubin that raised less in children younger than 2 years, the prevalence of other biochemical markers abnormality was comparable in different age groups. Conclusion: Hepatitis A infection is a common finding among Iranian children that equally occurs in boys and girls, while commonly appearing in children aged 7-18 years. The most frequent abnormal changes in laboratory parameters refer to change of liver enzymes, serum bilirubin, serum albumin and coagulated indices. [GMJ.2015;4(2):90-95]
Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010;28(41): 6653-7.
Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat 2008 15 Suppl 2: 69-72.
Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev. 2006;28:101–11.
Taylor RM, Davern T, Munoz S, Han S-H, McGuire B, Larson AM et al. Fulminant Hepatitis A Virus Infection in the United States: Incidence, Prognosis, and Outcomes. Hepatology. 2006;44(6):1589-97.
Tosti ME, Spada E, Romano L, Zanetti A, Mele A. Acute hepatitis A in Italy: incidence, risk factors and preventive measures. J Viral Hepat. 2008;15Suppl 2:26–32.
Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004;132(6):1005–22.
Payne L, Coulombier D. Hepatitis A in the European Union: responding to challenges related to new epidemiological patterns. Euro Surveill. 2009;14(3):1–2.
Castkova J, Benes C. Increase in hepatitis A cases in the Czech Republic in 2008—an update. Euro Surveill.2009;14(3):1–3.
Staes CJ, Schlenker TL, Risk I, Cannon KG, Harris H, PaviaAT, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics. 2000;106(4):E54.
D’Argenio P, Adamo B, Cirrincione R, Gallo G. The role of vaccine in controlling hepatitis A epidemics.Vaccine.2003;21(19–20):2246–9.
Kohl I, Nemecek V, Summerova M, Chlibek R, Nad’ova K, Minarikova O. Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks. Eur J Epidemiol. 2006;21(12):893–9.
Hanif M, Raza J, Qureshi H, Issani Z. Etiology of chronic liver disease in children. J Pak Med Assoc. 2004;54(3):119-22.
Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine 2000;18 (Suppl 1): 71-4.
Kara A, Parlakay AÖ, Akan A, Cengiz AB, Ceyhan M. Symptomatic Hepatitis A and Cholestatic Hepatitis as A Complication of Hepatitis A. J Pediatr Inf 2009; 3(4):165-7.
Çetinkaya B, Tezer H, ÖzkayaParlakay A, RevideSaylı T. Evaluation of pediatric patients with hepatitis A. J Infect DevCtries 2014; 8(3):326-30.
Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol 2010; 4(3): 68-73.
Victor JC, Surdina TY, Suleimenova SZ, Favorov MO, Bell BP, Monto AS. Person-to-person transmission of hepatitis A virus in an urban area of intermediate endemicity: implications for vaccination strategies. Am J Epidemiol. 2006;163(3):204-10.
Campagna M, Siddu A, Meloni A, Basciu C, Ferrai L, Pettinau A et al. Changing Pattern of Hepatitis A Virus Epidemiology in an Area of High Endemicity. Hepat Mon. 2012;12(6):382-5.
Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. Intervirology. 2010;53(1):15-9.
Stephen MF, Ian DG. Hepatitis A Virus (2000) In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Disease.ChurchillLivingstones, New York 1920-1940.
Koff RS. Hepatitis A. Lancet. 1998;351(9116):1643–9.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).